CVS Health Corp (CVS) Position Cut by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System cut its position in shares of CVS Health Corp (NYSE:CVS) by 3.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 61,300 shares of the pharmacy operator’s stock after selling 2,200 shares during the period. Louisiana State Employees Retirement System’s holdings in CVS Health were worth $4,444,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the business. SPC Financial Inc. raised its position in CVS Health by 5.2% during the fourth quarter. SPC Financial Inc. now owns 20,300 shares of the pharmacy operator’s stock worth $1,472,000 after acquiring an additional 1,000 shares during the period. Starfire Investment Advisers Inc. acquired a new stake in shares of CVS Health in the fourth quarter valued at about $447,000. KCS Wealth Advisory acquired a new stake in shares of CVS Health in the fourth quarter valued at about $355,000. CMH Wealth Management LLC raised its position in shares of CVS Health by 131.1% in the fourth quarter. CMH Wealth Management LLC now owns 30,425 shares of the pharmacy operator’s stock valued at $2,237,000 after buying an additional 17,260 shares during the last quarter. Finally, Hexavest Inc. raised its position in shares of CVS Health by 18.2% in the fourth quarter. Hexavest Inc. now owns 1,329,539 shares of the pharmacy operator’s stock valued at $96,392,000 after buying an additional 204,618 shares during the last quarter. Institutional investors own 83.23% of the company’s stock.

Shares of CVS Health Corp (CVS) opened at $70.66 on Wednesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.02 and a quick ratio of 0.52. CVS Health Corp has a 1-year low of $66.45 and a 1-year high of $84.00. The stock has a market cap of $72,944.85, a PE ratio of 10.92, a P/E/G ratio of 1.22 and a beta of 0.93.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.88 by $0.04. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The firm had revenue of $48.39 billion during the quarter, compared to analyst estimates of $47.54 billion. During the same quarter in the prior year, the firm posted $1.71 earnings per share. CVS Health’s quarterly revenue was up 5.3% on a year-over-year basis. research analysts expect that CVS Health Corp will post 6.38 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, February 2nd. Investors of record on Wednesday, January 24th were issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.83%. The ex-dividend date was Tuesday, January 23rd. CVS Health’s dividend payout ratio is currently 30.91%.

A number of equities research analysts have recently commented on the stock. Loop Capital reduced their target price on shares of CVS Health from $83.00 to $73.00 and set a “hold” rating for the company in a research report on Tuesday, November 7th. Morgan Stanley upgraded shares of CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 target price for the company in a research report on Friday, January 5th. Needham & Company LLC increased their target price on shares of CVS Health from $85.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. SunTrust Banks increased their target price on shares of CVS Health to $90.00 and gave the company a “buy” rating in a research report on Friday, January 5th. Finally, Leerink Swann set a $85.00 target price on shares of CVS Health and gave the company a “buy” rating in a research report on Friday, February 9th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $87.82.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares of the company’s stock, valued at $1,166,700. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.61% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “CVS Health Corp (CVS) Position Cut by Louisiana State Employees Retirement System” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://ledgergazette.com/2018/02/21/cvs-health-corp-cvs-position-cut-by-louisiana-state-employees-retirement-system.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply